Compound Evidence File
#EC-2026-0359
Proviron (Mesterolone)
Filed under Oral Tablets. The bureau holds 164 laboratory returns for this compound from 59 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
59 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 16 May 2026 | 14 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 16 Mar 2026 | 7 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Mar 2026 | 23 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Jan 2026 | 8 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 11 Apr 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 25 May 2026 | 16 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Jun 2026 | 15 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Feb 2026 | 17 Jun 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 10.0 | 10.0 | 10.0 | 9 Jun 2025 | 9 Jun 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 10.0 | 10.0 | 10.0 | 2 Jul 2025 | 2 Jul 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Jan 2026 | 2 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 5 Feb 2026 | 10 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Apr 2026 | 8 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Nov 2025 | 28 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Dec 2025 | 23 Apr 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Dec 2025 | 9 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Dec 2025 | 28 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Feb 2026 | 7 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 26 Feb 2026 | 14 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Nov 2025 | 3 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 9.9 | 5 Mar 2026 | 6 Mar 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 9.9 | 16 Feb 2026 | 11 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 9.9 | 18 Jul 2026 | 20 Jul 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 9.5 | 9.5 | 9.5 | 21 May 2025 | 21 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.9 | 7.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.8 | 8.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 8.7 | 8.7 | 8.7 | 7 May 2025 | 7 May 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.6 | 7.7 | 9.1 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.6 | 7.3 | 9.8 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.4 | 7.1 | 9.2 | 24 May 2026 | 24 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 11 | 8.0 | 6.0 | 9.9 | 27 Feb 2025 | 20 May 2026 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 8.0 | 8.0 | 8.0 | 6 May 2025 | 6 May 2025 |
| Peptide-SCASE #VI-2026-0111 | X | 7 | 7.7 | 6.4 | 9.8 | 27 Feb 2025 | 24 May 2026 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 7.6 | 7.6 | 7.6 | 7 May 2025 | 7 May 2025 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 7.5 | 7.5 | 7.5 | 16 Mar 2025 | 16 Mar 2025 |
| Shanghai Wibson Biotechnology WBSCASE #VI-2026-0214 | X | 1 | 7.1 | 7.1 | 7.1 | 11 Jun 2025 | 11 Jun 2025 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.9 | 6.8 | 7.0 | 11 Jun 2025 | 19 Jan 2026 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 6.9 | 6.9 | 6.9 | 2 Jul 2025 | 2 Jul 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 6.8 | 6.8 | 6.8 | 14 Jan 2025 | 14 Jan 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 6.7 | 6.7 | 6.7 | 3 Jul 2025 | 3 Jul 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 6.6 | 6.6 | 6.6 | 6 May 2025 | 6 May 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 6.4 | 6.4 | 6.4 | 6 May 2025 | 6 May 2025 |
| Pure RawzCASE #VI-2026-0767 | X | 1 | 6.3 | 6.3 | 6.3 | 24 Apr 2025 | 24 Apr 2025 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 6.2 | 4.5 | 9.2 | 3 Jun 2025 | 19 Jan 2026 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 6.0 | 6.0 | 6.0 | 17 Dec 2024 | 17 Dec 2024 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 5.9 | 5.9 | 5.9 | 20 Jun 2025 | 20 Jun 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | E | 2 | 5.8 | 4.2 | 7.3 | 6 May 2025 | 21 May 2026 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 5.8 | 5.8 | 5.8 | 2 Jul 2025 | 2 Jul 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 5 | 5.7 | 4.7 | 7.2 | 17 Dec 2024 | 24 May 2026 |
| Alpha-GenCASE #VI-2026-0905 | X | 3 | 5.7 | 4.1 | 6.5 | 2 Jul 2025 | 17 May 2026 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 5.7 | 5.7 | 5.7 | 17 Dec 2024 | 17 Dec 2024 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 5.4 | 5.4 | 5.4 | 8 Jul 2025 | 8 Jul 2025 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 4.9 | 4.9 | 4.9 | 3 Jul 2025 | 3 Jul 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 1.1 | 1.1 | 1.1 | 17 Dec 2024 | 17 Dec 2024 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.9 | 0.9 | 0.9 | 24 Apr 2025 | 24 Apr 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.7 | 0.7 | 0.7 | 25 Apr 2025 | 25 Apr 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 11 Jun 2025 | 11 Jun 2025 |
Open any subject to view the batch-level evidence for Proviron (Mesterolone) alone.